ライフサイエンスコーパス: PF

1 PF is a major complication following pancreaticoduodenec

2 PF may be difficult and potentially injurious to the don

3 PF Timolol group had significantly higher OSDI score, ba

4 PF was induced by repetitive intraperitoneal injections

5 PF(2) fit utilizes a fast polar Fourier search scheme, w

6 PF-00489791 was safe and generally well tolerated in thi

7 PF-00547659 is a fully human monoclonal antibody that bi

8 PF-04958242 significantly reduced ketamine-induced impai

9 PF-06747143 also induced cytotoxicity in AML cells via F

10 PF-3450074 (PF74), an HIV-1 capsid-targeting low-molecul

11 PF-46396 is chemically distinct from betulinic acid-deri

12 lead molecule from this series, compound 1 (PF-06827443), is a potent, low-clearance, orally bioavai

13 effort resulted in the identification of 11 (PF-06651600), a potent and low clearance compound with d

14 ious report, we discovered dicarboxylate 1a (PF-06649298) which inhibits the transport of citrate in

15 very resulted in potent pan-JAK inhibitor 2 (PF-06263276), which was advanced into clinical studies.

16 of these screening hits led to compound 22a (PF-543) with 2 orders of magnitude improved potency.

17 The enzyme phosphodiesterase 2A (PF-05270430) is a potential target for development of no

18 A total of 1110 patients were included (325 PF, 785 NF/NPF) with 7.7% reporting pain at median 33 mo

19 Compound 38 (PF-06767832) is a high quality M1 selective PAM that has

20 mbrane antigen (PSMA) and platelet factor-4 (PF-4) in serum were captured on the antibody-coated carb

21 e optimization of this series leading to 4a (PF-06761281), a more potent inhibitor with suitable in v

22 Compound 54 (PF-00299804) has been assigned the nomenclature of dacom

23 ), 88.9% (56.5-98.0), and 28.3% (17.9-41.6); PF - 11.6% (6.0-21.3), 88% (70.0-95.8), 0.9 (0.08-12.0),

24 ent, selective, brain penetrant compound 71 (PF-05085727) that effects in vivo biochemical changes co

25 "cold tracer" method, we have identified 8 (PF-06445974) as a promising PET lead.

26 These results suggest a PF drive for Ca(2+) signals during licking.

27 analyses demonstrated cost-savings down to a PF rate of 5.6%, up to a relative risk of PF of 0.775, a

28 ubgroup, posterior fossa ependymoma group A (PF-EPN-A), occurs in young children and appears to lack

29 pancreatic fistula/pancreatic leak/abscess (PF/PL/A) (21.9% to 9.2%).

30 inated in the identification of indole acid, PF-06409577 (7).

31 Here, we have demonstrated that activated PFs (aPFs) and myofibroblasts play a critical role in th

32 lating EGFR activation could protect against PF development caused by severe respiratory virus infect

33 re comparable to that of the reference agent PF-04937319 ( 154%).

34 , our data suggest that both PF-06649298 and PF-06761281 are allosteric, state-dependent SLC13A5 inhi

35 nic acid SLC13A5 inhibitors, PF-06649298 and PF-06761281, using a combination of (14)C-citrate uptake

36 steonecrosis was found for MTT (P = .09) and PF (P = .75) in the surrounding area.

37 wo compounds, PF-06649298 (compound 2: ) and PF-06678419 (compound 4: ), that inhibit human NaCT with

38 y directly suppressing ErbB3 activation, and PF in combination with erlotinib is much more effective

39 or progressive medullary thyroid cancer) and PF-04217903 block their activity at nanomolar concentrat

40 The association between diseases and PF varied severalfold (median, -1.4; range, -10.6 to 0.8

41 treated with a combination of erlotinib and PF compared to either agent alone.

42 Both FOLFIRINOX and PF-04136309 were simultaneously initiated with a total t

43 ltration rate between the RF study group and PF controls.

44 PDE4) inhibitors (rolipram, roflumilast, and PF-06266047) could mitigate behavioral deficits and cell

45 urs in the molecular subgroups ST-EPN-SE and PF-EPN-SE.

46 Urinary and PF LAM assays have low sensitivity but high specificity

47 significantly decreased in KEs (14-17%) and PFs (6-8%) at 24-48 h post-exercise, with greater reduct

48 significantly decreased in KEs (11-42%) and PFs (13-23%) at least at one time point post-exercise.

49 T2 values for each muscle composing KEs and PFs at proximal, middle, and distal sites were calculate

50 ggest that DR induces damage in both KEs and PFs, and especially affects proximal-middle sites of the

51 selective small-molecule NaV 1.7 antagonist PF-5198007.

52 itulated by the selective NaV 1.7 antagonist PF-5198007.

53 Additionally, the EP2 receptor antagonist (PF-04418948) or the EP4 antagonist (AE3-208) restored NE

54 new CXCR4 receptor antagonist IgG1 antibody (PF-06747143) binds strongly to AML cell lines and to AML

55 plants performed using the standard arterial PF technique served as a control group.

56 situated to provide synaptic Ca(2+) entry at PF-PC spines.

57 rtial desensitization of the CB1 receptor at PF-PC synapses.

58 e in bursts, and their parallel fibre axons (PFs) form approximately 180,000 excitatory synapses onto

59 versely, posterior fossa ependymoma group B (PF-EPN-B) tumours display frequent large-scale copy numb

60 5 years follow-up with no difference between PF- and NF-groups including subgroups of medial hernias.

61 were no pharmacokinetic interactions between PF-04958242 and ketamine.

62 hanism of action, our data suggest that both PF-06649298 and PF-06761281 are allosteric, state-depend

63 Furthermore, the onset of block by PF-05089771 develops with similar rates using protocols

64 The mechanism of action employed by PF-06446846 reveals a previously unexpected tunability o

65 Cln3(Deltaex7/8) brain, and were restored by PF-06266047.

66 t leukemic progenitors were also targeted by PF-06747143.

67 0.05), except for comparisons between the CA-PF, CAE-PE, and CA-PE groups.

68 elective NaV1.7 inhibitor clinical candidate PF-05089771 (34) which binds to a site in the voltage se

69 d peripherally restricted clinical candidate PF-06273340.

70 DME properties to deliver clinical candidate PF-06650833 (compound 40).

71 and models, suggest that permafrost carbon (PF-C) accumulated during the last glaciation may have be

72 of cerebellar parallel fiber-Purkinje cell (PF-PC) synapses and motor coordination in developing mic

73 s sanguinis, which was highly abundant in CF-PF.

74 e ability to stimulate, and the complemented PF-positive T. denticola strain restored the activation.

75 derivatives and the pyridone-based compound PF-46396.

76 Here, we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing th

77 Previous studies identified two compounds, PF-06649298 (compound 2: ) and PF-06678419 (compound 4:

78 Conclusion PF-03084014 was well tolerated and demonstrated promisin

79 Mutations that confer PF-46396 resistance can impose a defective phenotype on

80 Here we defined PF orthologs in Pseudomonas aeruginosa, Moraxella catarr

81 e peptide PFs with site-resolved NMR-derived PFs demonstrates high reliability and accuracy.

82 a subchondral area with low or no detectable PF and MTT adjacent to the joint surface, which was surr

83 h osteonecrosis, mean +/- standard deviation PF was 18.9 mL/100 mL per minute +/- 11.0 and mean MTT w

84 e, had relatively straight, smaller-diameter PF, and were not able to produce translational motility.

85 Consistent with this observed discrepancy, PF analysis revealed that FED exerted its effects throug

86 suggested that animals with a dysfunctional PF-pDMS pathway might suffer a deficit in creating or re

87 from HTS hit 5, IDO-1 inhibitor 6 (EOS200271/PF-06840003) has been developed.

88 Ophtalmologists should be aware that even PF formulations may lead to a mild ocular surface impair

89 Haemophilus influenzae protein F (PF) is an important virulence factor interacting with la

90 (18)F-PF-05270430 displayed fast and reversible kinetics in no

91 (18)F-PF-05270430 shows promise as a PDE2A PET ligand, albeit

92 ulted in a dose-dependent reduction of (18)F-PF-05270430 specific binding, with a half maximal effect

93 the nonhuman primate brain, uptake of (18)F-PF-05270430 was fast, with peak concentration (SUVs of 1

94 (18)F-PF-05270430 was radiolabeled by 2 methods via nucleophil

95 (18)F-PF-05270430 was synthesized in greater than 98% radioche

96 study was to evaluate the PDE2A ligand (18)F-PF-05270430, 4-(3-fluoroazetidin-1-yl)-7-methyl-5-(1-met

97 hosphodiesterase-2A (PDE2A) PET ligand (18)F-PF-05270430.

98 compete and counter-act for the power factor PF and figure-of-merit ZT.

99 rit (ZT)eng and an engineering power factor (PF)eng as functions of the temperature difference betwee

100 Preconcentration factor (PF) of 200 and the relative standard deviation (RSD) of

101 omputation of the average protection factor (PF) for peptides in isolation requiring no knowledge of

102 Pioneer factors (PFs) such as FOXA1 are able to directly access these cis

103 as improved, unchanged, or diminished FAQLQ-PF (>0.5 point decrease, a change of </=0.5 points, or >

104 al clinically important difference for FAQLQ-PF.

105 ciated with significant improvement in FAQLQ-PF (F = 3.63, P = .02), with mean difference 0.8 at 3 mo

106 Improvement in FAQLQ-PF and FAIM scores related specifically to acquisition o

107 Some patients with low FAQLQ-PF score (better QOL) at baseline deteriorated.

108 Allergy Quality of Life Questionnaire (FAQLQ-PF) and Food Allergy Independent Measure (FAIM) at pre-t

109 The FAQLQ-PF was administered to children aged 4-12 years undergoi

110 The change in the FAQLQ-PF was independent of the maximal tolerated dose at base

111 The total FAQLQ-PF score was inversely associated with the score at base

112 cial and Dietary Limitation, and total FAQLQ-PF scores improved significantly during the study period

113 BP activity inhibitors including Fatostatin, PF-429242, and Betulin on the cell cycle and determined

114 to the termination of DSE at parallel fiber (PF) to PC synapses and DSI at putative Stellate cell to

115 tant along the direction of parallel fibers (PFs), but fell off with distance along the orthogonal di

116 ls (PC) via the granule cell/parallel fibre (PF) pathway.

117 with early activation of portal fibroblasts (PFs) that express Thy-1, fibulin 2, and the recently ide

118 Peritoneal fibrosis (PF) is a serious complication in various clinical settin

119 Pulmonary fibrosis (PF) leads to progressive and often irreversible loss of

120 RS-CoV infection develop pulmonary fibrosis (PF), with higher prevalence in older patients.

121 ured AECs, and prevented pulmonary fibrosis (PF).

122 Based on these findings, PF-04449913 is being tested in phase 2 studies in patien

123 , titratable acidity (TA) and pulp firmness (PF).

124 reotide for reduction of pancreatic fistula (PF).

125 to compare the impact of permanent fixation (PF) with no fixation (NF)/nonpermanent fixation (NPF) of

126 ds and the presence of periplasmic flagella (PF) with pronounced spontaneous supercoiling.

127 played by T. denticola periplasmic flagella (PF), unique motility organelles of spirochetes, in stimu

128 he knee extensors (KEs) and plantar flexors (PFs) induced by downhill running (DR) by using transvers

129 xenografting, and multiplexed phospho-flow (PF) cytometric profiling to study drug response and iden

130 for mean transit time (MTT) and plasma flow (PF) were evaluated qualitatively and quantitatively.

131 c accuracy of urinary and pericardial fluid (PF) lipoarabinomannan (LAM) assays in tuberculous perica

132 Prograde flushing (PF) of living donor renal allografts with preservation s

133 Primordial follicle (PF) pool determines the availability of follicles for ov

134 For PF LAM strip tests, switching cut-points from grade 1 to

135 0.17% citric acid for TA, 0.72 and 12.2N for PF.

136 sential for somatic cell differentiation for PF formation.

137 aminin is thus a highly important target for PF orthologs of the bacterial species examined.

138 GF by FG-3019 might be a novel treatment for PF through the regulation of fibroblast and myofibroblas

139 onal-nucleosome-oriented accessing model for PFs seeking target motifs, in which FOXA1 can examine ea

140 s of the pulsar for a polarization fraction, PF = (20.9 +/- 5.0)%.

141 Tafluprost 0.0015% versus preservative free (PF) Timolol 0.1% eyedrops in ocular hypertensive (OH) an

142 Secondary transplantation of BM cells from PF-06747143-treated or IgG1 control-treated animals show

143 eted the Short Form 36 physical functioning (PF) scale over multiple survey cycles between 1992 and 2

144 Physical functioning (PF; QLQ-C30) and eating problems (EA; QLQ-OES24) were ch

145 spersed classes (UNEQ), potential functions (PF), and multivariate range modeling (MRM)) were applied

146 Furthermore, PF-04958242 was well tolerated.

147 aused by a contemporary Asian ZIKV strain (H/PF/2013), in part because this virus replicates less eff

148 M) structure of an infectious ZIKV (strain H/PF/2013, French Polynesia) in complex with the Fab fragm

149 In the circumscribed rim of high PF and intermediate MTT, which was only found in joints

150 rface, which was surrounded by a rim of high PF and intermediate MTT.

151 ions of interest were drawn in areas of high PF and long MTT on each parametric map.

152 showed a subchondral elongated area of high PF and low MTT that was surrounded by an area of long MT

153 ly pathogenic respiratory viruses.IMPORTANCE PF has many causative triggers, including severe respira

154 A significant difference (P < .001) in PF in the immediate subchondral area was found between T

155 -mediated disruption of the mutant allele in PF-382 cells markedly downregulated LMO2 expression, est

156 C6-C8) resulted in a significant decrease in PF formation by C8, suggesting that both BMP2 and E2 act

157 CTGF inhibition has anti-fibrotic effects in PF.

158 Heterozygous mutations were identified in PF-382 and DU.528 T-ALL cell lines in addition to 3.7% o

159 except for an increased tear instability in PF Timolol 0.1% group.

160 all GTPase, for its potential involvement in PF.

161 re associated with the greatest reduction in PF.

162 Unusually, postsynaptic Ca(2+) signalling in PF-PC spines does not involve ionotropic glutamatergic r

163 eedback as a potential therapeutic target in PF.

164 RTD in all phases, except for 0-200 ms in PFs, significantly decreased in KEs (11-42%) and PFs (13

165 In a bleomycin-induced PF model, mice deficient in p-rex1 had well-preserved al

166 CG-induced PF was significantly attenuated in FG-3019-treated mice.

167 nded phase 2 oral dose of the CCR2 inhibitor PF-04136309 in combination with FOLFIRINOX chemotherapy

168 linical-trial-tested Pyk2/FAK dual inhibitor PF-562271 reduced monosodium urate-mediated peritonitis,

169 Here we found that HSP90 inhibitor PF-4942847 and heat shock also suppress FOXM1.

170 ilized analogues of the maturation inhibitor PF-46396 as chemical tools to determine the chemical com

171 ty relationships of the maturation inhibitor PF-46396.

172 reatment of animals with the PDE2A inhibitor PF-05180999 resulted in a dose-dependent reduction of (1

173 afety and efficacy profile of PDE5 inhibitor PF-00489791 supports further investigation as a novel th

174 r therapy with the gamma-secretase inhibitor PF-03084014 in patients with recurrent, refractory, prog

175 ity, with the potent and selective inhibitor PF-06447475, rescues the observed defects in lysosomal m

176 eated with the CK1epsilon-specific inhibitor PF-4800567 (3-[(3-Chlorophenoxy)methyl]-1-(tetrahydro-2H

177 inistration of a CK1delta/epsilon inhibitor (PF-5006739) improved glucose tolerance in both DIO and g

178 n vivo, miR-193b mimetics and FAK inhibitor (PF-562271) each inhibited liposarcoma xenograft growth.

179 -dependent human Nav1.7 selective inhibitor (PF-05089771, IC50 = 11 nM) that interacts with the volta

180 ly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinational, multicente

181 so found for the selective NaV1.7 inhibitors PF-04856264 and phlotoxin 1.

182 four structurally unrelated PAK inhibitors (PF-3758309, FRAX486, FRAX597, and IPA-3) that act via di

183 mouse neurons with LRRK2 kinase inhibitors, PF-06447475 and MLi-2, blocks G2019S-LRRK2 effects, sugg

184 we test the ability of two S6K1 inhibitors, PF-4708671 and FS-115, to normalize translational homeos

185 ied hydroxysuccinic acid SLC13A5 inhibitors, PF-06649298 and PF-06761281, using a combination of (14)

186 INTERPRETATION: PF-00547659 was safe and well tolerated in this patient

187 (Arctic Ocean) as an archive to investigate PF-C destabilization during the last glacial-interglacia

188 while its isogenic nonmotile mutant lacking PF resulted in significantly diminished cytokine stimula

189 'High-impact' AMPAR potentiators like PF-04958242 may have a role in the treatment of the cogn

190 Lorlatinib (PF-06463922) is a next-generation small-molecule inhibit

191 Lorlatinib (PF-06463922) is an ALK/ROS1 inhibitor and is in clinical

192 inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor.

193 as surrounded by an area of long MTT and low PF.

194 jection of 7.5 mg, 22.5 mg, 75 mg, or 225 mg PF-00547659 or placebo at baseline, then every 4 weeks.

195 loro-4-methoxyphenyl)oxazole-4-carboxa mide (PF-04802367 or PF-367) has been identified as a highly p

196 wo different negative allosteric modulators, PF-06372222 and NNC0640, at 2.7 and 3.0 A resolution, re

197 ntromedian/parafascicular thalalmic nucleus (PF) and striatum might underlie such deficits.

198 iously that parafascicular thalamic nucleus (PF)-controlled neurons in the posterior dorsomedial stri

199 Weekly administration of PF-06747143 to leukemic mice significantly reduced leuke

200 pressed when treated with the combination of PF and erlotinib.

201 ools to determine the chemical components of PF-46396 that contribute to antiviral activity and Gag b

202 cular pathways underlying the development of PF are not well understood.

203 olerability, and recommended phase 2 dose of PF-04136309 plus FOLFIRINOX, with an expansion phase pla

204 Administration of a single dose of PF-06747143 to PDX models induced rapid malignant cell m

205 trongly potentiates the inhibitory effect of PF-04856264, a Nav1.7-specific blocker.

206 usion for 75 min during which the effects of PF-04958242/placebo were assessed on ketamine-induced: (

207 To characterize the effects of PF-06747143 on leukemia progression, we used two differe

208 been demonstrated to reduce the incidence of PF following pancreas resection; however, the drug cost

209 acterized the state-dependent interaction of PF-05089771 by systematically varying the voltage, frequ

210 A (11) C-isotopologue of PF-367 was synthesized and preliminary PET imaging studi

211 Whereas the kinetics of PF-367 binding in brain tissues are too fast for an effe

212 indings identify P-Rex1 as a novel player of PF, suggesting that targeting P-Rex1 may simultaneously

213 the inflammatory and fibrogenic processes of PF.

214 Taken together, the inhibitory profile of PF-05089771 suggests that a conformational change in the

215 peutic agent, the pharmacokinetic profile of PF-367 is ideal for discovery of radiopharmaceuticals fo

216 ong with the in vivo mouse CNS PK profile of PF-DcpSi (compound 24), one of the analogs found to be e

217 revent the onset or limit the progression of PF, and the molecular pathways underlying the developmen

218 ng variable perioperative mortality, rate of PF/PL/A, and readmission rates did not significantly alt

219 Relative risk of PF associated with pasireotide was estimated from the pu

220 After PD, the risk of PF is less than 1% if POD 1 drain amylase level is lower

221 a PF rate of 5.6%, up to a relative risk of PF of 0.775, and up to a drug cost of $2817.

222 e aimed to assess the efficacy and safety of PF-00547659 in patients with moderate to severe ulcerati

223 BMP2 receptors suppressed E2-stimulation of PF formation while knockdown of BMP2 in vitro significan

224 results show evidence for massive supply of PF-C from Siberian soils as a result of severe active la

225 Thawing of PF-C must also have brought about an enhanced organic ma

226 Our model advances the understanding of PF-PC LTD regulation and induction, and provides a valid

227 e consequences of the present-day warming of PF-C soils.

228 significantly upregulated the percentage of PFs in hamster fetal ovaries in vitro compared with eith

229 ts for the impact of 98 morbid conditions on PF.

230 ihydropyrimido[2,1-c][1,4]oxazin-4(9 H)-one (PF-06462894, 8), possessed favorable properties and a pr

231 henyl)oxazole-4-carboxa mide (PF-04802367 or PF-367) has been identified as a highly potent inhibitor

232 st 36 months with Tafluprost 0.0015% (27) or PF Timolol 0.1% (24) and 20 healthy age and sex-matched

233 ndomly assigned to receive placebo (n=73) or PF-00547659 at doses of 7.5 mg (n=71), 22.5 mg (n=72), 7

234 omized treatment periods of daily placebo or PF-04958242 for 5 days separated by a washout period.

235 reatment cycles, or in combination with oral PF-04136309, administered at a starting dose of 500 mg t

236 In parallel, PF profiling identified FED-mediated reduction in phosph

237 ,592 observations from 216,890 participants (PF mean score = 46.5 (standard deviation, 11)).

238 the method by comparison of average peptide PFs with site-resolved NMR-derived PFs demonstrates high

239 ic pasireotide is administered, the cost per PF/PL/A avoided is approximately $300,000.

240 The resultant cost per PF/PL/A avoided was $301,628.

241 with period-altering compounds: picrotoxin, PF-670462 (4-[1-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazo

242 ective concentration of 69.4 ng/mL in plasma PF-05180999 concentration.

243 LFIRINOX alone (n=8) or with FOLFIRINOX plus PF-04136309 (n=39).

244 e-escalation group receiving FOLFIRINOX plus PF-04136309 at 500 mg twice daily (n=6); this dose was e

245 Two (5%) patients in the FOLFIRINOX plus PF-04136309 group stopped treatment earlier than planned

246 77.0 days (70.0-90.5) in the FOLFIRINOX plus PF-04136309 group.

247 9%) of 33 patients receiving FOLFIRINOX plus PF-04136309 who had undergone repeat imaging achieved an

248 study assessed whether the AMPAR potentiator PF-04958242 would attenuate ketamine-induced deficits in

249 uced p53, PAI-1, and apoptosis and prevented PF, whereas overexpression of precursor-miR-34a increase

250 Bone morphogenetic protein 2 (BMP2) promotes PF formation by facilitating oocyte and granulosa cell d

251 In addition, highly purified PF were able to dose dependently stimulate cytokine TNF-

252 Wild-type T. denticola and the purified PF triggered activation of NF-kappaB through TLR2, as de

253 domly assigned 3:1, respectively, to receive PF-00489791 (20 mg) or placebo orally, once daily for 12

254 Patients received PF-04449913 once daily continuously until disease progre

255 n the dose de-escalation group that received PF-04136309 at the recommended phase 2 dose for assessme

256 enteen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles.

257 ed in at least 10% of the patients receiving PF-04136309 included neutropenia (n=27), febrile neutrop

258 se that inhibition of these channels reduces PF-PC excitatory postsynaptic currents and excitatory po

259 ve analogues retained the capacity to rescue PF-46396-dependent mutants (SP1-A3V, SP1-A3T, and CA-P15

260 tein, the main component of the spirochete's PF sheath, and a key determinant of the flagella's coile

261 luding data regarding clinically significant PF (International Study Group on Pancreatic Fistula Grad

262 Here, we studied PF to Purkinje cell synapses using trains of 100 Hz stim

263 owever, direct physical indications for such PF-C release have so far been absent.

264 que samples from caries-free tooth surfaces (PF) and from enamel carious lesions (PE) and dentin cari

265 system in a TLR2-dependent fashion and that PF are a key bacterial component involved in this proces

266 sing ribosome profiling, we demonstrate that PF-06446846 is highly selective for the inhibition of PC

267 The current study demonstrates that PF-05089771 exhibits a slow onset of block that is depol

268 such supercoiling, as well as the role that PF coiling plays in generating the characteristic hook-e

269 Taken together, our findings show that PF enhances the effect of erlotinib in ErbB3-expressing

270 We further show that PF-06446846 reduces plasma PCSK9 and total cholesterol l

271 ation and, thus, these findings suggest that PF-C may indeed have been an important source of CO2 acr

272 The PF train EPSC consisted of two components that were pres

273 Plasticity at the PF-PC synapse is considered to be a mechanism of informa

274 nd that this information is modulated by the PF-pDMS pathway.SIGNIFICANCE STATEMENT Individuals with

275 using contralateral cytotoxic lesions of the PF and pDMS (Group CONTRA) or ipsilateral control lesion

276 Premature depletion of the PF reserve leads to subfertility or infertility.

277 A crystal structure of the PF-06463922-ROS1 kinase complex revealed favorable inter

278 erved that a functional disconnection of the PF-posterior dorsomedial striatal pathway produces a spe

279 the pathogen L. interrogans, exposed on the PF surface, and named it Flagellar-coiling protein A (Fc

280 ple and safe, with results equivalent to the PF technique.

281 ed human embryonic 293 cell lines, while the PF-deficient mutants lacked the ability to stimulate, an

282 However, how these PFs interplay with nucleosomes remains to be elucidated,

283 Compared to PF Timolol 0.1%, Tafluprost 0.0015% showed similar safet

284 the synapse, although their contribution to PF-PC synaptic responses is unknown.

285 signaling as a key factor in progression to PF.

286 ovel analogues with decreasing similarity to PF-46396 to determine the chemical groups within PF-4639

287 Estradiol-17beta (E2) upregulates PF formation in developing hamster ovaries.

288 dated MWI weights diseases by severity using PF, a patient-centered outcome.

289 to baseline levels during follow-up, whereas PF and FA remained impaired 1 year postoperatively (Cohe

290 veal a high-affinity binding site with which PF-05089771 interacts, stabilizing the channel in a nonc

291 While PF(2) fit enables only a rigid, six dimensional (6D) ali

292 as blocked by inhibiting SphK1 activity with PF-543.

293 tive analogue is capable of interfering with PF-46396 inhibition of CA-SP1 cleavage.

294 reclinical (rat, NHP) and human studies with PF-04958242, and in silico modeling of AMPAR-NMDAR inter

295 CCR2-targeted therapy with PF-04136309 in combination with FOLFIRINOX is safe and t

296 sphorylation were observed when treated with PF.

297 8) in response to the 12-week treatment with PF-00489791 compared with placebo.

298 6396 to determine the chemical groups within PF-46396 that contribute to antiviral activity, Gag bind

299 17 and $31,950 for patients with and without PF, respectively.

300 gulates TGF-beta1-inducible activation of WT PFs by disrupting the formation of an inhibitory Thy-1-T